



BBCIC
Biologics & Biosimilars
Collective Intelligence Consortium

QUARTERLY



Letter From The Executive Director

Dear BBCIC Participants and Supporters,

A lot of exciting things are happening so far this year! BBCIC was first convened by AMCP in June of 2015. In the nine years since then we have grown from that start-up into a highly capable and respected organization with demonstrated expertise and a deep portfolio of publications and research accomplishments. Here are some highlights:

- 20 studies completed to date, including nine utilization analyses, five descriptive analyses, five methods and infrastructure studies, and one comparative safety and effectiveness study.
- Two active federal grants – cooperative agreements with FDA to demonstrate how real-world data from the U.S. and from countries outside the U.S. could be used for FDA regulatory decisions on biosimilars and interchangeable biosimilars.
- 16 peer-reviewed manuscripts have been published, and over 45 posters have been presented. AND COUNTING!

[Read More](#)

BBCIC Annual Meeting and Workshop



On June 11, BBCIC hosted our hybrid annual meeting at AMCP Headquarters in Alexandria, Va., and online. We had 13 participants in person in the office and another 25 joining us online for what was an interesting and engaging day. A few high points from the day were:

- We spent the morning in a workshop guided by our partners at the Patient Advocate Foundation and the Arthritis Foundation to learn how to transform our published manuscripts into patient-facing material – abstracts, infographics, etc.
- After lunch, our AMCP Professional and Government Affairs Team colleagues presented on some of the AMCP initiatives focusing on biosimilars.
- We then heard from our Science Committee Chair about the annual Research Topic Request process and the new online form to capture project ideas.

- The group then discussed our Steering Committee and Science Committee structure and activities, and talking through next steps for both Committees.
- We closed out the day by hearing from project leads on our current research initiatives, including:
 - Two Active FDA Grants.
 - The Effect of COVID Lockdowns on Non-COVID-Related Treatment and Outcomes in IBD.
 - Patient access to bevacizumab and trastuzumab biologics and the impact of biosimilars.
 - Switching Events and Product Utilization for Targeted Immunomodulators in Patients with Rheumatoid Arthritis.
 - AMCP Research Institute launch!

Detailed notes from the meeting will be shared with all BBCIC participants. Thank you for your enthusiasm and engagement!


New Publications

We are pleased to announce we have one newly published manuscript and one new manuscript that has been accepted for publication by the *Journal of Managed Care & Specialty Pharmacy*!

The newly published manuscript can be found at: [The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review](#)

The new manuscript that was accepted for publication is titled “Utilization and Patient Characteristics for the Trastuzumab Reference and Biosimilars, and Other HER2 Inhibitors in the United States” and it will be available on the *JMCP* website in the coming months.

Abstract Tracker



Manuscript Tracker

